- Projekty SAV
- Medzinárodná spolupráca
- Centrá a vedecké parky SAV
- Špičkové vedecké tímy a pracovníci SAV (ext)
- Centrá excelentnosti SAV
- Štrukturálne fondy EÚ
- Evaluácia, akreditácia v SAV
- Výskumná infraštruktúra SAV
- Infraštrukt. SAV v kontexte EÚ
[Euronanomed3] Help in finding partners for submission
Dear ENM III colleagues participating in the 2017 call
I would like to help an Israeli researcher to find partners for submission.
His very short research outline is pasted below. I would thank you if you could disseminate it in your regional/ national channels.
Thank you for your help.
Subject: Looking to integrate in ENM III Call for 2017 - Development and Applications of CRISPR-Cas9 for Genome Editing.
Ayal Hendel is a PI whose goal is to develop effective, safe and definitive therapy for patients with monogenic diseases such as severe combined immunodeficiency (SCID) using the CRISPR-Cas9 technology. These days he is establishing his new lab in the Institute for Nanotechnology and Advanced Materials at BIU and the overall focus of the lab is to develop the next wave of curative therapies for SCIDs and other hematopoietic disorders using genome editing. During his training at Stanford, he was the first to demonstrate that chemical alterations to synthesized single guide RNAs enhance Cas9-mediated genome editing efficiency in human primary HSPCs (Hendel et al. Nature Biotechnology. 2015) and now he is continuing this research in his own lab. In Israel there is a unique population of SCID patients and therefore he plans to translate his basic science studies to use in SCID patient-derived HSPCs in methodical, careful and pre-clinically relevant fashion.